Loading...
XOSL
GENT
Market cap63mUSD
Jul 28, Last price  
40.00NOK
1D
0.50%
1Q
-1.48%
Jan 2017
-24.53%
IPO
42.86%
Name

Gentian Diagnostics ASA

Chart & performance

D1W1MN
XOSL:GENT chart
P/E
46.65
P/S
3.50
EPS
0.86
Div yield, %
1.01%
Shrs. gr., 5y
0.10%
Rev. gr., 5y
20.89%
Revenues
176m
+16.06%
22,893,74224,554,41625,586,95430,896,88734,988,95946,108,22047,952,00068,369,00083,122,000101,636,000136,193,000152,070,000176,499,000
Net income
13m
-70.73%
873,987-2,908,559-3,222,155-8,926,987-15,169,906-19,798,354-39,857,000-17,114,000-24,794,000-24,001,000-10,648,00045,293,00013,256,000
CFO
43m
+216.49%
2,433,754-1,950,715-4,626,008-7,901,630-18,632,886-10,896,653-21,483,000-7,661,000-27,053,000-13,952,00015,458,00013,457,00042,590,000
Dividend
May 06, 20260.6 NOK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
IPO date
Dec 14, 2016
Employees
55
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT